瑞典非免疫旅行者使用蒿甲醚-苯芴醇治疗无并发症恶性疟疾的治疗失败率高:有效性与病例系列的回顾性比较分析
该研究回顾性分析2000-2015年斯德哥尔摩成人恶性疟疾治疗,比较蒿甲醚-苯芴醇(AL)与其他口服方案的有效性。AL失败均见于欧洲男性,该组有效率仅73.7%(95%CI 48.8%-90.0%)。
要点
- AL治疗非免疫成人恶性疟疾的失败率高于其他口服方案。
- 欧洲男性使用AL后治疗失败风险显著升高,有效率仅73.7%。
- AL失败者基因分型证实复发,未发现临床显著耐药标记,部分提示苯芴醇浓度不足。
核心结论
- 非免疫成人使用6剂AL方案后症状性晚期治疗失败率高,尤其见于男性。
研究设计与样本
- 回顾性比较分析,纳入2000-2015年斯德哥尔摩成人恶性疟疾397例。
主要发现
- 310例仅口服治疗(95例AL、162例甲氟喹、36例阿托伐醌-氯胍、17例其他),87例初始静脉治疗后口服。
- 5例AL晚期治疗失败,1例阿托伐醌-氯胍缓慢应答;AL失败均见于欧洲男性,该组有效率73.7%(95%CI 48.8%-90.0%)。
- 基因分型证实初始寄生虫种群复发,耐药标记未显示临床显著耐药模式;至少2例提示苯芴醇浓度低于治疗水平。
临床怎么用
- 临床医生应知晓非免疫成人使用AL后数周寄生虫复现的风险,并告知患者。
- 需建立成人AL的最佳剂量方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria. Since the introduction of artemether-lumefantrine (AL) for treatment of uncomplicated malaria in Sweden, treatment failures have been reported in adults. METHODS: A retrospective comparative analysis of treatment regimen for P. falciparum malaria in adults in Stockholm during 2000-2015 was performed to evaluate the effectiveness of AL. Parasite genotyping and drug concentrations were investigated in the AL treatment failures. RESULTS: Among the total 397 P. falciparum episodes, 310 were treated with oral regimen only (95 AL, 162 mefloquine, 36 atovaquone-proguanil [AP], and 17 others), and 87 were administered initial intravenous therapy (38 artesunate and 49 quinine) followed by oral treatments. Five late treatment failures were detected after AL and one slow response to AP. The effectiveness of AL alone was 94.7% (95% confidence interval [CI], 88.1%-98.3%), compared with 99.5% for other oral regimens (P = .003). All AL failures occurred in European men and the effectiveness in this group was only 73.7% (95% CI, 48.8%-90.0%). Genotyping confirmed recrudescence of the initial parasite populations and drug resistance markers revealed no clinically significant resistance patterns. Lumefantrine concentrations suggested subtherapeutic concentrations in at least 2 cases. CONCLUSIONS: Our findings indicate a high rate of symptomatic late treatment failures after 6-dose AL regime in nonimmune adults, especially in men. Our report warrants the need to establish optimal dosing of AL in adults and to alert clinicians about the importance of informing patients regarding the risk of parasites reappearing weeks after AL treatment.
引用
- Sondén K, Wyss K, Jovel I, et al. High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clin Infect Dis. 2016. PMID: 27986683. doi:10.1093/cid/ciw710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。